{"id":33844,"date":"2025-11-03T17:40:48","date_gmt":"2025-11-03T12:10:48","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=33844"},"modified":"2025-10-31T12:09:14","modified_gmt":"2025-10-31T06:39:14","slug":"lupus-nephritis-drugs","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-drugs","title":{"rendered":"New Lupus Nephritis Drugs on the Horizon: 6 Promising Therapies Eyeing Newly Approved GAZYVA\u2019s Market Space"},"content":{"rendered":"\n

Roche\u2019s GAZYVA FDA approval has already rewritten the lupus nephritis playbook \u2014 it turned a long-standing oncology B-cell drug into a validated, kidney-saving option. It proved that aggressive B-cell targeting can materially boost complete renal responses when added to standard therapy. The GAZYVA approval<\/a> (driven by the phase II NOBILITY and phase III REGENCY data<\/strong>) gives clinicians a new, evidence-backed tool to chase remission, pressures payers and guideline panels to rework algorithms, and forces rivals to prove either better efficacy, safer long-term profiles, or meaningful convenience advantages. Can Roche keep the lead? Short answer: Maybe \u2014 but the field is noisy and fast. Several promising lupus nephritis drug rivals are charging up the pipeline and could nibble at GAZYVA\u2019s advantage if they show complementary wins. Currently, Novartis <\/strong>is leading with three lupus nephritis drugs in its pipeline. AstraZeneca and Cabaletta Bio<\/strong> are not far behind, with two and one candidates, respectively, in their pipelines. Let\u2019s take an in-depth review of these six upcoming lupus nephritis drugs<\/a>.<\/p>\n\n\n\n

Novartis\u2019 Ianalumab, FABHALTA, and YTB323<\/strong><\/p>\n\n\n\n

Novartis is currently developing its three lead candidates, Ianalumab, FABHALTA, and YTB323, for the treatment of lupus nephritis. Ianalumab is a fully human, HuCAL-derived monoclonal antibody targeting the BAFF receptor (BAFF-R)<\/strong> and is administered subcutaneously. It is designed to induce direct ADCC-mediated B-cell depletion and is being evaluated for autoimmune hepatitis, idiopathic pulmonary fibrosis, systemic lupus erythematosus (SLE), and lupus nephritis. The lupus nephritis drug is currently in Phase III clinical development<\/strong>, with Novartis aiming to submit for regulatory approval around 2028<\/strong>.<\/p>\n\n\n\n

FABHALTA (iptacopan)<\/strong>, an oral Factor B inhibitor<\/strong>, is being explored as a potential treatment for lupus nephritis, building on its proven efficacy in other complement-mediated kidney disorders, such as IgAN, PNH, and C3G. While lupus nephritis-specific results are still awaited, its robust mechanistic rationale and growing commercial momentum, reflected in USD 129 million<\/strong> in 2024 sales, highlight its promise in addressing proliferative lupus nephritis.<\/p>\n\n\n\n

YTB323 <\/strong>is a CD19-targeted CAR-T cell therapy<\/a> designed to restore immune tolerance by eliminating autoreactive B cells. Developed using Novartis\u2019 T-Charge platform, the treatment is currently in Phase II trials<\/strong>, with a regulatory submission focused on lupus nephritis anticipated after 2027<\/strong>.<\/p>\n\n\n\n

\"Lupus-Nephritis-Therapies-in-Pipeline\"<\/a><\/figure>\n\n\n\n

AstraZeneca\u2019s SAPHNELO and ULTOMIRIS<\/strong><\/p>\n\n\n\n

AstraZeneca\u2019s SAPHNELO (anifrolumab)<\/strong>, a type I interferon receptor blocker, is advancing through Phase III trials <\/strong>for lupus nephritis. Already approved for SLE in more than 65 countries, the drug has demonstrated promising steroid-sparing benefits and durable remission. Nonetheless, its once-every-four-week IV administration and lack of a subcutaneous formulation limit its convenience compared to BENLYSTA. At the same time, obinutuzumab\u2019s<\/strong> stronger CRR outcomes in Phase II trials<\/strong> pose a notable competitive challenge. <\/p>\n\n\n\n

Meanwhile, ULTOMIRIS (ravulizumab)<\/strong>, a long-acting inhibitor of complement C5<\/strong>, is currently in Phase II trials<\/strong> for the treatment of Class III\/IV lupus nephritis. Although specific efficacy data in lupus nephritis are not yet available, the drug\u2019s proven success in other complement-driven conditions, such as aHUS, PNH, and NMOSD, yielding global sales of USD 3.9 billion<\/strong> in 2024, underscores its potential in lupus nephritis based on mechanistic rationale.<\/p>\n\n\n\n

Cabaletta Bio\u2019s CABA-201<\/strong><\/p>\n\n\n\n

CABA-201<\/strong> is a fully human CD19-directed chimeric antigen receptor (CAR) T-cell therapy<\/strong> that incorporates a 4-1BB co-stimulatory domain. Cabaletta is conducting RESET (REstoring SElf-Tolerance) Phase I\/II trials<\/strong> across multiple autoimmune indications, including lupus nephritis, systemic lupus erythematosus, myositis, systemic sclerosis, and generalized myasthenia gravis, with the potential to extend to a broad spectrum of other autoimmune disorders.<\/p>\n\n\n\n

Roche\u2019s GAZYVA approval represents more than just a clinical milestone \u2014 it\u2019s a commercial and strategic inflection point. By successfully repositioning an oncology drug for an autoimmune indication, Roche has opened a lucrative new therapeutic frontier while validating the broader B-cell depletion class. However, the approval also shifts the benchmark for future entrants: efficacy alone may no longer suffice. Upcoming competitors will need to show faster onset, sustained remission with reduced steroid dependency, or a more favorable safety profile to justify share capture and payer adoption.<\/p>\n\n\n\n

The competitive lupus nephritis pipeline<\/a> paints a dynamic picture. Novartis\u2019 diversified strategy, spanning antibody, complement, and CAR-T modalities, signals a long-term bet on precision immune modulation in renal autoimmunity. AstraZeneca, meanwhile, is banking on its expertise in the interferon pathway to defend and expand its lupus franchise. At the same time, Cabaletta Bio\u2019s autologous CAR-T approach introduces a bold, potentially one-time curative paradigm. If these candidates deliver, Roche may find itself defending its first-mover advantage not just in nephrology clinics, but also across policy, pricing, and patient access fronts.<\/p>\n\n\n\n

In the near term, GAZYVA\u2019s success is expected to drive broader acceptance of combination regimens targeting B cells and complement cascades, while accelerating investment in cell-based and gene-modified immunotherapies. Yet the long-term winner in lupus nephritis may not be the drug with the deepest depletion, but the one that most effectively restores immune balance with minimal toxicity. Roche has set the pace \u2014 but the race to redefine lupus nephritis treatment has only just begun.<\/p>\n\n\n\n

\"Lupus-Nephritis-Market-Assessment\"<\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"

Roche\u2019s GAZYVA FDA approval has already rewritten the lupus nephritis playbook \u2014 it turned a long-standing oncology B-cell drug into a validated, kidney-saving option. It proved that aggressive B-cell targeting can materially boost complete renal responses when added to standard therapy. The GAZYVA approval (driven by the phase II NOBILITY and phase III REGENCY data) […]<\/p>\n","protected":false},"author":14,"featured_media":33846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[22745,6248,22750,6250,17782,6249],"industry":[17225],"therapeutic_areas":[17230],"class_list":["post-33844","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-gazyva","tag-lupus-nephritis","tag-lupus-nephritis-drugs","tag-lupus-nephritis-market","tag-lupus-nephritis-pipeline","tag-lupus-nephritis-therapy","industry-pharmaceutical","therapeutic_areas-genito-urinary-system-and-sex-hormones"],"acf":[],"yoast_head":"\n6 New Lupus Nephritis Drugs to Watch Out For<\/title>\n<meta name=\"description\" content=\"Novartis is leading with three drugs in its pipeline. AstraZeneca & Cabaletta Bio are with two and one candidates, respectively.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-drugs\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"6 New Lupus Nephritis Drugs to Watch Out For\" \/>\n<meta property=\"og:description\" content=\"Novartis is leading with three drugs in its pipeline. AstraZeneca & Cabaletta Bio are with two and one candidates, respectively.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-drugs\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-03T12:10:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/30173657\/lupus-nephritis-drugs.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"6 New Lupus Nephritis Drugs to Watch Out For","description":"Novartis is leading with three drugs in its pipeline. AstraZeneca & Cabaletta Bio are with two and one candidates, respectively.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-drugs","og_locale":"en_US","og_type":"article","og_title":"6 New Lupus Nephritis Drugs to Watch Out For","og_description":"Novartis is leading with three drugs in its pipeline. AstraZeneca & Cabaletta Bio are with two and one candidates, respectively.","og_url":"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-drugs","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2025-11-03T12:10:48+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/30173657\/lupus-nephritis-drugs.webp","type":"image\/webp"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-drugs","url":"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-drugs","name":"6 New Lupus Nephritis Drugs to Watch Out For","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-drugs#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-drugs#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/30173657\/lupus-nephritis-drugs.webp","datePublished":"2025-11-03T12:10:48+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Novartis is leading with three drugs in its pipeline. AstraZeneca & Cabaletta Bio are with two and one candidates, respectively.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-drugs"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/lupus-nephritis-drugs#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/30173657\/lupus-nephritis-drugs.webp","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/30173657\/lupus-nephritis-drugs.webp","width":466,"height":284,"caption":"lupus-nephritis-drugs"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2025\/10\/30173657\/lupus-nephritis-drugs-300x183.webp","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">GAZYVA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Lupus nephritis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Lupus Nephritis Drugs<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Lupus nephritis market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Lupus Nephritis Pipeline<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Lupus nephritis therapy<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">GAZYVA<\/span>","<span class=\"advgb-post-tax-term\">Lupus nephritis<\/span>","<span class=\"advgb-post-tax-term\">Lupus Nephritis Drugs<\/span>","<span class=\"advgb-post-tax-term\">Lupus nephritis market<\/span>","<span class=\"advgb-post-tax-term\">Lupus Nephritis Pipeline<\/span>","<span class=\"advgb-post-tax-term\">Lupus nephritis therapy<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 5 months ago","modified":"Updated 5 months ago"},"absolute_dates":{"created":"Posted on Nov 3, 2025","modified":"Updated on Oct 31, 2025"},"absolute_dates_time":{"created":"Posted on Nov 3, 2025 5:40 pm","modified":"Updated on Oct 31, 2025 12:09 pm"},"featured_img_caption":"lupus-nephritis-drugs","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33844","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=33844"}],"version-history":[{"count":4,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33844\/revisions"}],"predecessor-version":[{"id":33851,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/33844\/revisions\/33851"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/33846"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=33844"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=33844"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=33844"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=33844"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=33844"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}